During development of mangafodipir as an MRI contrast agent, it was discovered that it possessed MnSOD mimetic activity.
As mangafodipir was being developed as a new MRI contrast agent, researchers discovered that it had properties similar to those of manganese superoxide dismutase (MnSOD).